Blue Earth Diagnostics, a Bracco Company, Appoints Marco Campione as Chief Executive Officer

July 9, 2024 – Bracco and Blue Earth Diagnostics, a Bracco subsidiary and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, announced the appointment of Marco Campione as their new Chief Executive Officer (CEO), reporting to Bracco Imaging CEO Fulvio Renoldi Bracco. Campione also joins the board of Blue Earth Diagnostics Ltd. and will serve as Vice Chairman of the Board of Blue Earth Diagnostics Inc. Dr. David Gauden, co-founder of Blue Earth Diagnostics and with the company since 2014, is becoming full-time CEO of Bracco’s subsidiary, Blue Earth Therapeutics. The changes reflect a carefully planned strategy to drive continued growth, development and opportunity for both companies and Bracco.

According to a written statement announcing his appointment, Marco Campione has more than 25 years of experience at GE HealthCare, where he most recently served as executive chairman and global head of Contrast Media, general manager of Pharmaceutical Diagnostics North America and president of GE HealthCare Inc.

“I congratulate Marco Campione on his appointment as CEO and we look forward to benefiting from his strategic, operational and broad business expertise as we expand our global leadership in the diagnostic radiopharmaceuticals industry,” said Fulvio Renoldi Bracco, CEO of Bracco Imaging. He added: “Marco joins Bracco Group at a pivotal moment in our evolution as the company matures, broadens its global horizons and expands its commercial presence… I also want to take this opportunity to recognize David Gauden’s many contributions to the success of Blue Earth Diagnostics and wish him well as he leads Blue Earth Therapeutics as full-time CEO.”

“I am excited and honored to assume the role of CEO of Blue Earth Diagnostics,” Campione said in a written statement released today. “The company is a recognized leader in the nuclear medicine and oncology communities with a strong reputation for successful innovation, execution and dedicated service to patient health,” he added.

Blue Earth Diagnostics, an indirect subsidiary of Bracco Imaging SpA, is a growing international molecular imaging company founded in 2014 that develops and commercializes positron emission tomography (PET) radiopharmaceuticals for imaging and therapeutic applications, according to a company statement.

Bracco Imaging SpA, part of the Bracco Group, is a global provider of diagnostic imaging services headquartered in Milan, Italy, that develops, manufactures and markets diagnostic imaging agents and solutions. It offers a portfolio of products and solutions for all key diagnostic imaging modalities: X-ray imaging (including computed tomography-CT, interventional radiology and cardiac catheterization), magnetic resonance imaging (MRI), contrast-enhanced ultrasound (CEUS) and nuclear medicine using radioactive tracers and new PET imaging agents to inform clinical management and guide the care of oncology patients in areas of unmet medical need. The company reports that in 2019, Bracco Imaging expanded its product portfolio by expanding its nuclear imaging solutions for oncology in the urology segment and other specialties with the acquisition of Blue Earth Diagnostics, and in 2021, Bracco Imaging formed Blue Earth Therapeutics as a separate, cutting-edge biotechnology vehicle to develop radiopharmaceutical therapies.

For more information, visit www.braccoimaging.com